# Biodep

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biodep

- Industry: Biotechnology
- Headquarters: Jiangyin, China
- Website: www.mbioda.com
- Latest round: Series B (Jan 11, 2024)
- Investors on record: 6

## About

Established in 2017 and based in Jiangyin, China, Biodep operates as a probiotics and derivatives developer that provides probiotic lyophilized powder, probiotic solid drinks, and yogurt fermentation agents. The company has a factory and acquired HACCP, ISO22000, FDA, and NSF certifications. In January 2024, Biodep closed a series B+ funding.


The company's products are divided into five series, which include probiotics powder, probiotics capsules, probiotic tablets, cold brew freeze-dried coffee, and probiotic yogurt blocks, which are exported to 20 countries and regions including the Americas, Europe, and Australia. Products are applied in the fields of foodstuff, healthy food, cosmetics, environmental treatment, and modern agriculture.

The company will use the series B+ funds for the field of probiotics and biotechnology.

## Funding rounds

- Series B, Jan 11, 2024 — CMB International Asset Management, GF Xinde Investment, HHF Fuyuan Investment
- Series B, Dec 17, 2020 — Houji Capital, Guolian Group
- Angel, Jan 24, 2019 — Jinkong Qiyuan Capital

## Investors

- Jinkong Qiyuan Capital (https://capitalatlas.ai/funds/jinkong-qiyuan-capital) — Angel
- Houji Capital (https://capitalatlas.ai/funds/houji-capital) — Series B
- Guolian Group (https://capitalatlas.ai/funds/guolian-group) — Series B
- CMB International Asset Management (https://capitalatlas.ai/funds/cmb-international-asset-management) — Series B
- GF Xinde Investment (https://capitalatlas.ai/funds/gf-xinde-investment) — Series B
- HHF Fuyuan Investment (https://capitalatlas.ai/funds/hhf-fuyuan-investment) — Series B